Ballentine Partners LLC decreased its position in shares of Shire PLC (NASDAQ:SHPG) by 53.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,115 shares of the biopharmaceutical company’s stock after selling 1,255 shares during the quarter. Ballentine Partners LLC’s holdings in Shire were worth $202,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently bought and sold shares of SHPG. PointState Capital LP grew its holdings in shares of Shire by 4,642.0% during the second quarter. PointState Capital LP now owns 711,296 shares of the biopharmaceutical company’s stock valued at $120,067,000 after buying an additional 696,296 shares during the last quarter. LMR Partners LLP purchased a new stake in Shire in the second quarter worth approximately $55,664,000. SG Americas Securities LLC boosted its holdings in Shire by 1,634.4% in the second quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock worth $32,671,000 after purchasing an additional 182,388 shares during the last quarter. Chescapmanager LLC purchased a new stake in Shire in the second quarter worth approximately $19,144,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Shire by 179.9% in the first quarter. Dimensional Fund Advisors LP now owns 167,133 shares of the biopharmaceutical company’s stock worth $24,968,000 after purchasing an additional 107,417 shares during the last quarter. Hedge funds and other institutional investors own 17.88% of the company’s stock.
SHPG opened at $181.80 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.02 and a current ratio of 1.55. Shire PLC has a 1-year low of $123.73 and a 1-year high of $182.36. The company has a market capitalization of $51.44 billion, a price-to-earnings ratio of 12.00, a price-to-earnings-growth ratio of 1.56 and a beta of 1.19.
SHPG has been the topic of several research reports. ValuEngine cut shares of Shire from a “hold” rating to a “sell” rating in a report on Thursday, September 6th. Royal Bank of Canada set a $195.00 target price on shares of Shire and gave the stock a “buy” rating in a report on Tuesday, October 23rd. BidaskClub upgraded shares of Shire from a “hold” rating to a “buy” rating in a report on Wednesday, October 24th. Evercore ISI cut shares of Shire from an “outperform” rating to a “market perform” rating and set a $196.00 target price on the stock. in a report on Tuesday, September 4th. Finally, Berenberg Bank cut shares of Shire from a “buy” rating to a “hold” rating in a report on Friday, September 7th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Shire presently has an average rating of “Buy” and an average price target of $201.11.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Recommended Story: How to Invest in Growth Stocks
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.